Cyclopharm Limited provided sales guidance for the half year ended 30 June 2022. The company expected revenue is expected to be approximately $11.3 million, 36% higher than pcp and 74% higher than the company's pre-COVID revenues in first half 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.435 AUD | +3.99% | -13.03% | -25.45% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.45% | 101M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- CYC Stock
- News Cyclopharm Limited
- Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022